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Abstract
Background: The goal of this study was to evaluate the somatic and psychological effects by means of QUALITY
OF LIFE (QOL) of surgical treatment of patients with oral squamous cell carcinoma. The factors gender, age,
nicotine consumption, and tumour stage were taken into consideration.
Methods: 54 patients after surgical resection of oral squamous cell carcinomas (OSCC) were analysed from
01.09.2005 to 31.05.2008. Inclusion criteria for the study were: age at least 18 years, no indication or treatment of
synchronous and metachronous tumours.
German translations of the EORTC H&N-35 and EORTC QLQ-C-30 questionnaires, as well as a general socioeco-
nomic patient history were used as measuring instruments. The questionnaires were completed independently by
the patients. The answers were translated into scale values for statistical evaluation using appropriate algorithms.
Results: Analysis of the EORTC-QLQ-C-30 questionnaires demonstrated a tendency of more negative assessment of
emotional function among the female participants, and a more negative evaluation of social function among the
male participants. Greater tumour sizes showed significantly lower bodily function (p = 0.018). While a smaller
tumour size was significantly associated with lower cognitive functioning (p = 0.031). Other cofactors such as age,
nicotine consumption, and tumour stage only showed a tendency to influence the quality of sleep and daily life.
Conclusions: The data obtained within this investigation demonstrated that gender had the most significant
power on the subjectively perceived postoperative quality of life. This factor is important e.g. in preoperative
decision making regarding immediate microvascular reconstruction after e.g. mandibular resection and therefore
QOL assessment should become integral component of the care of patients with OSCC.
Background
The treatment of head and neck malignancies involves
surgical resection and adjuvant radio- and/or che-
motherapy, if indicated. The main patient’s concerns are
survival time, and the secondary functional deficits
resulting from surgery and adjuvant therapy. Therapeu-
tic success should not only be measured on absence of
recurrence and metastases, but also on the characteris-
tics that indicate the QOL, which is defined according
to the WHO (1947) as the factors in life of an individual
that are important to him or her and as complete physi-
cal, mental, and social well-being. Other authors affiliate
health associated QOL with the difference between the
expectations of a patient, and the status that is achiev-
able [1]. Shumaker defines QOL as a subjective evalua-
tion in which the level of health, medical care, and
supportive therapy influence the human capacity to
achieve and maintain one’s goals in life [2].
QOL studies give the clinician information on the
effects of diseases, their treatments, and the side effects
of these [2]. Patients benefit from such studies, as they
can define the most disturbing aspects of the disease,
and can contribute to therapy decisions, because an
increase in survival time is not necessarily associated
with an improvement in the QOL [3]. In previous stu-
dies, the complaints associated with disease and treat-
ment were assessed worse by patients themselves than
by the attending physicians [4,5]. Hence, a patient’s
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treatment results.
QOL studies are an established instrument in oncolo-
gical research in developed countries [6-8]. However,
QOL is difficult to evaluate, and can only be measured
indirectly. Questionnaires on this offer the advantage
that the most common complaints can be compiled in a
structured manner.
The European Organization for Research and Treat-
ment (EORT) introduced a questionnaire (Quality of
Life Questionnaire 30-QLQ-C30) that evaluates general
aspects of QOL associated with various tumours. This
questionnaire has gained worldwide acceptance, and has
been translated into many different languages [9,10].
This questionnaire contains a special section for head
and neck tumours: 35-QLQ-H&N35 [11].
The number of publications concerning the measure-
ment of QOL in patients with head and neck tumours
has risen recently [8,12,13]. Typical Head and neck
tumours treated by maxillofacial surgeons influence
multiple functions, including respiration, food intake,
speech, and socialisation through aesthetic impairment
[10]. These are a heterogeneous group of tumours,
although they belong to the same patho-anatomical
family: oral cavity, oropharynx, larynx, hypopharynx,
nasopharynx, sinus, and salivary gland tumours. The
various entities influence different functions, and thus
the QOL, in ways that must be distinguished. Differ-
ences between the oral cavity and oropharynx entities
were first described in a study by Chandu [7].
Up to now, very few other studies differentiate
between the various head and neck tumours. Previous
investigations were limited to oral and oropharyngeal
tumours [8,14].
In the current study, the EORTC-QLQ-C30 and its
special questionnaire QLQ-H&N35 were used to evalu-
ate a group of patients with oral malignant tumours
with special focus on the influences of age, gender, nico-
tine consumption, and tumour stage.
Methods
In a cross-sectional study, 73 patients with oral squa-
mous cell carcinomas of the tongue, gingiva, buccal
mucous membrane, hard and soft palates, and floor of
the mouth were evaluated at one month following com-
pletion of surgical therapy in the Department of Oral
and Maxillofacial Surgery at the university hospital in
Aachen, Germany from 01.09.2005 to 31.05.2008. All
patients received free flap reconstruction after tumorre-
section by the same operational team with at least one
decade of experience in this operational field. One sur-
geon performed tumorresection and flapraising, the
other surgeon always performed neck dissection and
reconstruction. The study was approved by the local
ethics committee, and all patients signed a written con-
sent form.
Exclusion criteria for the study were: poor general
health, serious coexisting disease, synchronous and
metachronous tumours, recurrence of malignancy, and
psychological or psychomotoric dysfunction that would
hinder adequate completion of the questionnaire.
Among the 73 patients who consented to participate in
this study, 54 patients completed the QOL assessment
criteria and were eligible for evaluation (Table 1). 19
Patients could not be included on the grounds that they
were deceased, unable to be reached by telephone or
mail, or declined to participate for personal reasons.
The patient data were gathered with a socioeconomic
questionnaire containing data about age, gender, marital
status, level of education, occupation, coexisting dis-
eases, nicotine and alcohol consumption, and tumour
stage and localisation at the time of diagnosis. QOL was
evaluated using the EORTC-QLQ-C30 Version 3.0 and
its supplement H&N35, in German translation [15].
The patients completed the questionnaire in the pre-
sence of an expert, who was able to assist in case of dif-
ficulties in understanding the questions, but did not
influence the answers. The EORTC-QLQ-C30 question-
naire is concerned with malignant diseases and their
treatment in general, and contains 30 questions. These
Table 1 Characteristics of all 54 patients in the study,
Data are number (%) of patients
Total n
(%)
Male n
(%)
Female n
(%)
Age Median (SD) 60 (11) 60 (10) 61 (14)
Gender 54 (100) 31 (57) 23 (43)
Level of education
completed
A-levels 11 (20) 9 (17) 2 (4)
6 year secondary school 9 (17) 6 (11) 3 (6)
Basic secondary school 33 (61) 15 (28) 18 (33)
No diploma 1 (2) 1 (2) 0 (0)
T
< 4 cm (T 1-2) 44 (81) 26 (48) 18 (33)
> 4 cm (T 3-4) 10 (19) 5 (9) 5 (9)
Alcohol consumption
Never 5 (9) 2 (4) 3 (6)
Seldom 43 (80) 26 (48) 17 (31)
Regularly 6 (11) 3 (6) 3 (6)
Nicotine consumption
Yes 29 (54) 16 (30) 13 (24)
No 25 (46) 15 (28) 10 (19)
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functioning (mobility, ability to work, emotional stress,
cognitive stress, and social stress), general symptoms
and problems (fatigue, nausea and vomiting, pain, dys-
pnea, sleep disturbances, lack of appetite, constipation,
diarrhea, and financial burden) and general level of
health/quality of life. The answer possibilities for the
topic “general health and quality of life” encompass a
scale from 1 - 7, where 1 represents the appraisal “very
poor”,a n d7“excellent”.T h et o p i c s“global functioning”
and “general symptoms and problems” have the answer
alternatives 1 (not at all), 2 (somewhat), 3 (moderate),
and 4 (extreme). The answers to the individual ques-
tions are represented on a scale of 0 - 100. A high score
on the scale represents severe problems [16].
The EORTC-H&N-35 describes the disease specific
QOL in the head and neck malignancies. The question-
naire is a supplement to the QLQ-C30, and contains
35 questions. There are 7 scaled answers for pain, swal-
lowing, sensibility, speech, eating in a social setting, social
contact, and sexuality. Further, 11 individual topics are
evaluated taking localisation, symptoms, and treatment
into account (dental problems, mouth opening, dry
mouth, poor salivation, cough, sense of illness, analgesic
use, nutrition difficulties, gastric tube, weight loss or
gain). Analogous to the QLQ-C30, the answers are repre-
sented on a scale of 0-100, and a high score on the scale
of symptoms describes severe problems [16]. The scores
of each of these questionnaires were interpreted accord-
ing to the EORTC guidelines. The statistical analysis of
the data was completed using SPSS1 version 14.0 (SPSS
Inc.). A p-value < 0.05 was considered as statistically sig-
nificant. The descriptive statistics were conducted using
the absolute and relative frequencies of the qualitative
variables. The distribution of quantitative variables was
determined using the mean and standard deviation
(determined as normal or abnormal using the Kolmo-
gorov-Smirnov test). The Mann-Whitney U - or the
Kruskall-Wallis tests were used to compare various
groups of quantitative variables, as these demonstrated
an abnormal distribution. Qualitative variables were ana-
lysed using the Chi
2 test or Fisher’s exact test.
Results
Tables 2, 3, 4, and 5 show the distribution of medians
and interquartile ranges of the scales function, symp-
toms, and for general health and quality of life for the
EORTC-QLQ-C30 questionnaire, comparing the patient
groups according to gender, nicotine consumption, age
(< 60 years and > 60 years), and tumour stage.
The gender dependent analysis of quality of life
obtains the trend that emotional functioning, composed
of the factors tension, worry, irritability, and depression
was judged to be worse by the females (Table 2). In
contrast, the male group demonstrated higher scores
(poorer function) for social functioning, which incorpo-
rated familial and general relations with other persons.
The male participants tended to rate worse on the func-
tional and environmental symptom scales for dyspnea,
sleep disorders, and financial stress. A comparison of
the genders in relation to the tumour specific symptoms
indicated that the females tended to show more severe
symptoms in swallowing, salivation, and coughing as
well as weight loss (5 kg for females vs. 2 kg for males).
Smokers generally tended to score worse than non-
smokers in emotional, social, cognitive, and role func-
tioning and revealed more sleep dysfunction (Table 3).
Non-smokers judged the symptoms of dyspnea and
Table 2 EORTC QLQ-C30 Gender
male P50 [P25-P75] n (31) female P50 [P25-P75] n (23) P value
General health 33 [16-50] 33 [16-50] 0.837
Bodily function 75 [47-86] 73 [47-80] 0.979
Role functioning 33 [0-83] 33 [0-67] 0.928
Emotional functioning 50 [33-75] 67 [50-75] 0.340
Cognitive functioning 67 [0-83] 67 [0-83] 0.484
Social functioning 50 [0-67] 16 [0-67] 0.789
Fatigue 33 [10-67] 33 [0-67] 0.676
Nausea/Vomiting 0 [0-33] 0 [0-33] 0.844
Pain 33 [33-67] 33[0-67] 0.606
Dyspnea 33[30-33] 0 [0-66] 0.483
Sleep disorders 66 [0-100] 33 [33-87] 0.415
Loss of appetite 33 [0-67] 0 [0-67] 0.288
Constipation 0 [0-33] 0 [0-100] 0.592
Diarrhea 0 [0-33] 0 [0-33] 0.711
Financial stress 33 [0-67] 0 [0-67] 0.770
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tumour specific symptoms speech, swallowing, social
contact, and dental health were worse in the smoker’s
group. The non-smokers had more complaints of dry
mouth and cough. The smokers lost, with a median of
4 kg, more weight in comparison to the non-smokers
with a median of 2 kg.
The degree of discrimination for ascertaining the sig-
nificance levels was determined for a tumour size of
4 cm, with the stages T1/2 versus T3/4. The greater
tumour sizes T3/4 exhibited a significantly lower bodily
function (p = 0.018; Table 4). Emotional functioning
was given the worst assessment by participants in stage
T4. While cognitive and social functioning was rated to
be very high by patients with a tumour size of at least
2 cm (T2-T4), it was found to be statistically significant
that a smaller tumour size was associated with lower
cognitive functioning (p = 0.031). On the symptom
scales, a smaller tumour size (T1/2) was associated with
more sleep disorders. No clear tendencies could be
found comparing the tumour specific symptom scales
for the various tumour stages, however speech and
social contact tended to show the worst values for the
stages T1/2. Weight loss increased with greater tumour
s i z e( m e d i a nv a l u e s :T 1=2k g ,T 2=5 . 5k g ,T 3u n d
T4 = 7kg).
Table 3 EORTC QLQ-C30 Nicotine consumption
Smoker P50 [P25-P75]
n (29)
Non-smoker P50 [P25-P75]
n (25)
P value
General health 33 [16-50] 33 [0-41,5] 0.116
Bodily function 75 [53.5-86] 73 [43.5-80] 0.589
Role functioning 50 [0-91.5] 33 0-67] 0.327
Eotional functioning 67 [33-74] 58 [16.5-75] 0.495
Cognitive functioning 67 [0-83] 67 [0-83] 0.978
Social functioning 50 [0-75] 16 [0-67] 0.416
0.937
Fatigue 33 [5-67] 33 [5,5-67] 0.639
Nausea/Vomiting 0 [0-33] 0 [0-33] 0.244
Pain 33[0-67] 33 [33-67] 0.953
Dyspnea 16.5 [0-66] 33 [0-33] 0.389
Sleep disorders 66 [33-100] 33 [0-100] 0.135
Loss of appetite 0 [0-33] 33 [0-100] 0.827
Constipation 0 [0-83.5] 0 [0-67] 0.730
Diarrhea 0 [0-33] 0 [0-33] 0.654
Financial stress 0 [0-67] 33 [0-67] 0.116
Table 4 EORTC QLQ-C30 T- Stage
T1 P50 [P25-P75]
n [34]
T2 P50 [P25-P75]
n [10]
T3 P50 [P25-P75]
n [3]
T4 P50 [P25-P75]
n [7]
p[T1/T2-T3/T4]
General health 33 [12-50] 29 [12-37.5] 33 [16-50] 33 [25-33] > 0.999
Bodily function 75 [53-81.5] 83 [58.5-86.25] 40 [13-73] 67 [27-75] 0.018
Role functioning 16.5 [0-67] 58.5 [12-100] 33 [17-100] 50 [0-67] 0.432
Emotional functioning 58 [0-77] 74 [45.75-79.25] 75 [67-92] 33 [33-67] 0.719
Cognitive functioning 25 [0-75] 71 [0-83] 67 [0-100] 83 [67-83] 0.031
Social functioning 16 [0-67] 67 [0-87.25] 50 [0-67] 50 [0-67] 0.752
Fatigue 27.5 [0-58.75] 61.5 [24.75-67] 100 [22-100] 67 [0-100] 0.098
Nausea/Vomiting 0 [0-20.25] 8 [0-37.25] 50 [33-100] 0 [0-16] 0.187
Pain 33 [0-67] 58.5 [0-71] 33 [33-83] 33 [0-83] 0.800
Dyspnea 33 [0-66] 33 [0-50] 33 [0-33] 16.5 [0-49.75] 0.846
Sleep disorders 66 [24.75-100] 50 [25.75-100] 33 [0-33] 33 [0-100] 0.218
Loss of appetite 0 [0-41.4] 33 [0-67] 100 [0-100] 0 [0-67] 0.475
Constipation 0 [0-100] 0 [0-0] 0 [0-33] 0 [0-67] 0.630
Diarrhea 0 [0-33] 0 [0-33] 0 [0-100] 0 [0-33] 0.438
Financial stress 0 [0-67] 33 [-75.25] 0 [0-67] 33 [0-100] 0.614
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the tendency to be age-related as it was determined to be
better for patients under 60 years (p = 0.051; Table 5).
Discussion
OSCC and its treatment directly affect health-related
QOL. The most basic functions of speech, chewing and
swallowing are frequently altered, while symptoms such
as pain and psychosocial issues like appearance and
emotional functioning can also be problematical.
Most studies that are concerned with QOL for head
and neck tumours do not differentiate between the sub-
groups of various tumour localisations. Some investiga-
tors criticise the heterogeneity of these studies, since
large differences in the assessment of QOL could be
found between the individual localisations with the
questionnaires [17]. Other authors have negated these
differences [18].
At present, there is no universally accepted QOL ques-
tionnaire for patients with OSCC, which results in diffi-
culties when attempting to compare the outcome of
different institutions [19]. Therefore the established
EORTC-QLQ-C30/H&N-35 and the questionnaires were
used in this study. In a comparison of different question-
naires like the University of Washington (UW) Head and
Neck Disease-Specific Measure, the Medical Short Form
36 and the EORTC-H&N35, the latter was more sensitive
in detecting changes in the single items of speech and
swallowing, and furthermore the UW-QOL does not
explore emotional, cognitive and social function [20].
Other authors found that the UW-QOL scale is most sui-
table for surgical patients [21]. Our experience has
c o n f i r m e dt h a tt h e6 5i t e m so ft h eE O R T C - Q L Q - C 3 0 /
H&N-35 cover most important issues of patients receiv-
ing treatment for head and neck cancer and provides a
reasonable assessment. Two studies have been published
that measured QOL at time of diagnosis using the
EORTC-QLQ-C30/H&N35. In the Netherlands a study
with 80 patients demonstrated QOL before therapy for
oral and oropharyngeal tumours correlated with tumour
localisation, stage, and comorbidity [6]. Patients with oral
cavity (mobile tongue, gums, floor of the mouth, buccal
mucosa, hard palate and buccal area of the soft palate)
tumours reported more pain than patients with orophar-
yngeal (located behind the anterior pillar of the pharynx,
retromolar trigone, tonsils, tonsillar region of the soft
palate and base of tongue) tumours. Patients with
advanced stage tumours (T3/4) showed more obstruction
to mouth opening and a higher sense of illness than
patients with T1/2 tumours.
In a multi-centre study of 357 patients with head and
neck tumours in Sweden and Norway, differences in
quality of life were determined for tumour localisation
(patients with oral tumours reported more pain),
advanced tumour stage, gender (females scored more
poorly on the emotional scale), and age (patients over
65 years showed better scores on the emotional and
social scales) [22].
The present cross-sectional study shows that the
scales for general health/quality of life, role and social
functioning were negatively influenced, in contrast to
the scales for bodily, emotional functioning and cogni-
tive functioning, which tended to be rated more
positively.
With regard to symptom assessment, fatigue, pain,
dyspnoea, sleep disorders, and financial stress were
rated more negatively than the symptoms nausea and
vomiting, lack of appetite, constipation, and diarrhea.
Some studies did not observe any differences between
the genders [20]. In our study, females tended to show
more negative scores in most of the function subgroups,
especially for emotional functioning, which consisted of
the factors tension, worry, irritability, and depression.
Furthermore, the female gender also demonstrated
worse ratings for swallowing, salivation, and coughing.
In contrast, the male group rated social functioning
more negatively, which encompassed the areas of famil-
ial and general relations with other persons. The males
tended to score dyspnea, sleep disorders, and financial
stress more negatively, which resulted in a higher level
of psychological stress as compared to the female gen-
der. The results of another study were contrary [22].
Bjordal showed that QOL assessment was lower for
females, but these values equalised after one year, when
more mental changes, alcohol problems, and poor nutri-
tion were found among the males [10].
Table 5 EORTC QLQ-C30 Age
Age <60 P50
[P25-P75]
n [27]
Age >60 P50
[P25-P75]
n [27]
P value
General health 33 [16-50] 33 [16-50] 0.784
Bodily function 75 [33-86] 73 [53-80] 0.917
Role functioning 50 [0-67] 17 [0-83] 0.495
Emotional functioning 67 [33-75] 58 [0-75] 0.553
Cognitive functioning 67 [0-83] 67 [0-83] 0.679
Social functioning 67 [0-83] 0 [0-67] 0.051
Fatigue 55 [33-67] 22 [0-67] 0.083
Nausea/Vomiting 0 [0-16] 0 [0-33] 0.520
Pain 50 [0-83] 33 [0-50] 0.093
Dyspnea 33 [0-66] 16.5 [0-33] 0.537
Sleep disorders 33 [33-100] 33 [0-100] 0.761
Loss of appetite 0 [0-67] 0 [0-33] 0.379
Constipation 0 [0-67] 0 [0-33] 0.925
Diarrhea 0 [0-33] 0 [0-0] 0.097
Financial stress 33 [0-100] 0 [0-67] 0.361
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correspond with age, since tumour diagnoses among
females were made at an older age, and mostly at an
earlier stage than in males. The correlation between age
and many of the QOL subgroups, such as the bodily
symptoms of dry mouth and dental problems can be
explained by natural physical decline in advanced age
[8]. The social and emotional subgroups are two excep-
tions, since the assessment of these by younger patients
is normally more negative than by older patients [23].
Contrary to this, the present study showed a higher eva-
luation of social function by patients less than 60 years.
In the present study, smokers tended to demonstrate a
lower evaluation of social, emotional, cognitive, and role
functioning than non-smokers. For non-smokers, the
symptoms of dyspnea and financial stress were judged
to be worse than by smokers. The smokers however
exhibited greater sleep dysfunction, and a more negative
impact on speech, swallowing, loss of social contact, and
dental problems, some of which could be explained by
withdrawal symptoms. Complaints of dry mouth and
cough were increased among non-smokers, symptoms
that can be triggered by nicotine consumption.
Posterior localised tumours demonstrate a worse prog-
nosis, since these often remain unnoticed in screening
examinations, and once symptoms arise from regional
lymph node metastases, the tumours are at an advanced
stage at time of initial diagnosis [24,25].
At the time of diagnosis, the non-specific symptoms of
oral tumours include fatigue, nausea, vomiting, and loss
of appetite. Fatigue and loss of appetite can be explained
by a decline in the general state of health through an
advanced stage tumour. Oral tumours, especially those
in the posterior region can stimulate the emetic impulse,
and can obstruct the passage of a bolus during swallow-
ing, and induce nausea and vomiting in this manner.
Despite the fact, that in the present study all opera-
tions were performed by the same team, the surgeons
dexterity always biases surgical related investigations. To
our knowledge no study exists so far, which has been
able to eliminate this bias.
Conclusions
Prospective QOL assessment can provide valuable addi-
tional information for both the treatment team and the
patients. In addition, it gives an opportunity to support
routine medical follow up. The present study included
only patients with oral tumours from the heterogenous
group of head and neck malignancies. Hence, the num-
ber of patients was limited, which influenced non-signif-
icant results, and might explain the contrary nature of
the results, in comparison to the existing literature.
Even oral tumours are heterogenous, and tumours in
the anterior region of the floor of the mouth show
different symptoms than posterior tumours, or malig-
nancies in the buccal or palatal regions. With regard to
QOL studies, a more specific differentiation in this area
is desirable. Consequently, further prospective studies
must explore this topic with larger patient collectives.
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